Primary Hyperoxaluria Treatment Market
Market Insights on Primary Hyperoxaluria Treatment covering sales outlook, demand forecast & up-to-date key trends
Primary Hyperoxaluria Treatment Market by Type, Route of Administration, Distribution Channel, Drug Class & Region | Forecast 2023 to 2033
Primary Hyperoxaluria Treatment Market Snapshot (2023 to 2033)
The global primary hyperoxaluria treatment market is expected to garner a market value of US$ 18 million in 2023 and is expected to accumulate a market value of US$ 41.07 million by registering a CAGR of 8.6% in the forecast period 2023 to 2033. The market for primary hyperoxaluria treatment registered a CAGR of 5.2% in the historical period 2018 to 2022.
Primary hyperoxaluria (PH) is a rare genetic disorder that affects the liver's ability to metabolize oxalate, leading to the formation of kidney stones and progressive kidney damage. The primary hyperoxaluria treatment market includes drugs and therapies aimed at reducing the production of oxalate in the body, managing symptoms, and preventing complications.
Some of the primary hyperoxaluria treatments available in the market include Lumasiran (Oxlumo), an RNA interference (RNAi) therapeutic that works by blocking the production of the enzyme that produces oxalate in the liver. The drug was approved by the FDA in 2020 for the treatment of PH type 1 in children and adults; Oxalate-degrading enzymes that can break down oxalate in the gut, reducing the amount of oxalate that is absorbed into the bloodstream; Kidney stone management and Dialysis and kidney transplant.
The primary hyperoxaluria treatment market is relatively small due to the rarity of the disease, but with the approval of Lumasiran, there is a growing focus on developing new therapies for the condition. Some companies currently working on PH treatments include Dicerna Pharmaceuticals, Alnylam Pharmaceuticals, and Allena Pharmaceuticals.
|
Report Attribute |
Details |
|
Expected Market Value (2023) |
US$ 18 million |
|
Anticipated Forecast Value (2033) |
US$ 41.07 million |
|
Projected Growth Rate (2023 to 2033) |
8.6% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
2018 to 2022 Primary Hyperoxaluria Treatment Market Demand Analysis vs. Forecast 2023 to 2033
According to market research and competitive intelligence provider, Future Market Insights- the market for Primary Hyperoxaluria Treatment reflected a value CAGR of 5.2% during the historical period, 2018 to 2022. One of the key drivers of market growth is the increasing prevalence of primary hyperoxaluria. While the condition is rare, its incidence has been steadily increasing in recent years, which is expected to drive demand for effective treatments.
The approval of Lumasiran in 2020 has also been a major boost to the market, as it represents the first targeted therapy for primary hyperoxaluria type 1. The drug has shown promising results in clinical trials, and its approval is expected to drive further research and development in the field.
In addition, the growing focus on precision medicine and personalized treatments is expected to drive innovation in the primary hyperoxaluria treatment market. With the increasing availability of genetic testing and personalized medicine, there is an opportunity to develop targeted therapies that are tailored to individual patients' genetic profiles.
The primary hyperoxaluria treatment market is expected to continue to grow in the coming years as new treatments are developed and approved, and as the demand for effective therapies for this rare disease continues to increase. Overall, the market for Primary Hyperoxaluria Treatment is expected to register a CAGR of 8.6% in the forecast period ranging from 2023 to 2033.
Which are Some Prominent Drivers of the Primary Hyperoxaluria Treatment Market?
Increasing Prevalence of Primary Hyperoxaluria to push market growth
The increasing prevalence of primary hyperoxaluria is expected to be a significant driver of market growth in the primary hyperoxaluria treatment market. While the condition is considered rare, its incidence has been steadily increasing in recent years.
Primary hyperoxaluria is a genetic disorder that affects the liver's ability to metabolize oxalate, which can lead to the formation of kidney stones and progressive kidney damage. According to the National Institutes of Health (NIH), the estimated prevalence of primary hyperoxaluria ranges from 1 in 100,000 to 1 in 1,000,000 individuals worldwide.
However, recent studies have suggested that the actual prevalence of the condition may be higher than previously thought. For example, a study published in the American Journal of Kidney Diseases in 2019 estimated that the incidence of primary hyperoxaluria in the United States is closer to 1 in 45,000 individuals.
As the prevalence of primary hyperoxaluria continues to increase, there is likely to be greater demand for diagnosis and treatment of the condition, which is expected to drive growth in the primary hyperoxaluria treatment market. In addition, as more people are diagnosed with the condition, there is likely to be greater interest and investment in research and development of new treatments, which could further boost market growth.
Overall, the increasing prevalence of primary hyperoxaluria is expected to be a significant driver of market growth, as it is likely to lead to greater demand for effective treatments and increased investment in the development of new therapies.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhat are the Challenges Faced by the Primary Hyperoxaluria Treatment Market?
Expensive Cost of Treatment to restrict Market Growth
One of the significant challenges faced by the PKU therapeutics market is the lack of awareness and underdiagnosis of the disorder. Primary hyperoxaluria is a rare disease, and as a result, there is limited awareness of the condition among healthcare providers and the general public. This can lead to delays in diagnosis and treatment, which can negatively impact patient outcomes.
Moreover, developing new treatments for rare diseases such as primary hyperoxaluria can be challenging, as the regulatory environment can be complex and uncertain. This can lead to delays in bringing new therapies to market. Overall, while there have been some recent advances in the primary hyperoxaluria treatment market, there are still several challenges that need to be addressed to improve patient outcomes and ensure the development of more effective and accessible treatments.
Region-Wise Insights
How is the Primary Hyperoxaluria Treatment Market Turning Out in the South & East Asia Region?
Increasing awareness and diagnosis of the condition Shaping Landscape for Primary Hyperoxaluria Treatment in South & East Asia
The primary hyperoxaluria treatment market is still developing in the South & East Asia region, and there is limited data available on the prevalence and treatment of the condition in the region. However, there have been some recent developments that suggest that the market is starting to grow in this region.
For example, in 2020, the pharmaceutical company Alnylam Pharmaceuticals announced that its drug Lumasiran, the first targeted therapy for primary hyperoxaluria type 1, had received regulatory approval in Japan. This was a significant development, as Japan is a major market in the South & East Asia region and has a well-established healthcare system. The approval of Lumasiran in Japan is likely to increase awareness of primary hyperoxaluria in the region and could lead to greater demand for diagnosis and treatment of the condition.
In addition, there have been some recent studies that suggest that the prevalence of primary hyperoxaluria may be higher in certain parts of the South & East Asia region than previously thought. For example, a study published in the Journal of the American Society of Nephrology in 2020 found that the prevalence of primary hyperoxaluria type 1 was higher in parts of India than previously reported. This suggests that there may be a significant unmet need for primary hyperoxaluria treatment in the region.
Overall, while the primary hyperoxaluria treatment market is still developing in the South & East Asia region, recent developments suggest that there is growing interest and investment in this area. As awareness of the condition increases and more effective treatments become available, it is likely that the market will continue to grow in the region.
What are the Factors Boosting the Market for Primary Hyperoxaluria Treatment in North America?
Increasing Focus on Technological Advancements shaping Landscape for Primary Hyperoxaluria Treatment in North America
The market for primary hyperoxaluria treatment in North America is expected to grow due to several factors. One of the primary drivers of market growth is the relatively high prevalence of primary hyperoxaluria in the region, particularly primary hyperoxaluria type 1. According to the National Institutes of Health (NIH), the estimated prevalence of primary hyperoxaluria type 1 in the United States is approximately 1 in 100,000 individuals. This high prevalence of the condition is expected to drive demand for effective treatments in the region.
Another factor that is contributing to market growth in North America is the increasing awareness and diagnosis of primary hyperoxaluria. There is growing recognition of the condition among healthcare professionals, which is leading to more accurate diagnosis and treatment of the condition. This is particularly true for primary hyperoxaluria type 1, which is often diagnosed in childhood. As more people are diagnosed with the condition, there is likely to be greater demand for effective treatments.
Advances in the development of treatments for primary hyperoxaluria are also driving market growth in North America. Lumasiran, a drug that targets the underlying genetic cause of primary hyperoxaluria type 1, was approved by the USA Food and Drug Administration (FDA) in 2020. This has led to greater interest and investment in the development of new therapies, which is expected to boost market growth.
In addition, favorable reimbursement policies in North America are making primary hyperoxaluria treatment more accessible to patients. For example, kidney transplantation, which is a treatment option for some patients with end-stage renal disease caused by primary hyperoxaluria, is typically covered by insurance in North America. This makes it easier for patients to access the treatment they need.
Finally, North America has a strong healthcare infrastructure that is able to support the development and delivery of new treatments for primary hyperoxaluria. This includes specialized centers for the treatment of rare diseases, which can provide comprehensive care for patients with the condition. The strong healthcare infrastructure in North America is expected to contribute to continued growth in the primary hyperoxaluria treatment market in the region.
Overall, the combination of high prevalence, increasing awareness and diagnosis, advances in treatment options, favorable reimbursement policies, and a strong healthcare infrastructure is expected to drive growth in the primary hyperoxaluria treatment market in North America.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Category-Wise Insights
By Route of Administration, Which Segment is Likely to Account for a Significant Share?
Parenteral route of administration to hold a significant share and push market growth
The injectable route of administration is likely to account for a significant share of the Primary Hyperoxaluria Treatment market. Currently, the only approved therapy for the treatment of primary hyperoxaluria is Lumasiran, which is administered via subcutaneous injection. Therefore, the subcutaneous injection route of administration is expected to account for a significant share of the primary hyperoxaluria treatment market.
However, there are also other therapies currently in development for the treatment of primary hyperoxaluria that may use different routes of administration. For example, some gene therapy approaches are being developed that would involve the delivery of a therapeutic gene via a viral vector. These therapies may use an intravenous infusion or other routes of administration. Overall, while the subcutaneous injection route of administration is currently dominant in the primary hyperoxaluria treatment market, the development of new therapies may lead to the use of different routes of administration in the future.
By Distribution Channel, Which Segment is Likely to Account for a Significant Share?
Hospital pharmacies segment to hold a significant share and push market growth
Hospitals and specialty clinics are often the first point of contact for patients with Primary Hyperoxaluria, as they provide specialized care and access to diagnostic tools and treatments. These facilities also have the expertise and resources to provide comprehensive care to patients with complex or severe cases of Primary Hyperoxaluria.
In addition, many of the treatments for Primary Hyperoxaluria require specialized administration or monitoring, such as intravitreal injections or electroretinography testing, which are typically performed in hospitals or specialty clinics. This further contributes to the dominance of these distribution channels in the Primary Hyperoxaluria Treatment market.
Overall, hospitals and specialty clinics are likely to continue to account for a significant share of the Primary Hyperoxaluria Treatment market, driven by the specialized care and expertise they provide. However, as patient preferences and healthcare delivery models continue to evolve, the market share of the various distribution channels may shift over time.
Market Competition
Key players in the market include companies such as Competition Deep Dive, Alnylum Pharma, OxThera, Dicerna Pharmaceuticals, Inc., Allena Pharmaceuticals, Biocodex, Tecoland Corporation, Zhejiang Tianxin Pharmaceutical Co., Takeda Pharmaceuticals, Wuxi Further Pharmaceutical Co Ltd, Genentech, along with healthcare providers and technology companies among other global players.
- In 2020, The United States Food and Drug Administration (FDA) gave the green light to Oxlumo (lumasiran) as the initial treatment for primary hyperoxaluria type 1 (PH1), a rare hereditary disorder. This groundbreaking approval is the culmination of the work of specialists and community members coordinated by the Oxalosis & Hyperoxaluria Foundation and the Kidney Health Initiative.
- The approval of Oxlumo was a result of input from patients, treating physicians, experts, and sponsors at a patient-focused drug development meeting and through other collaborative efforts. Oxlumo's function is to reduce the production of oxalate in patients with PH1. The drug was evaluated in two separate trials in PH1 patients: a randomized, placebo-controlled trial in patients aged six years and older, and an open-label study in patients under six years old. The patients ranged in age from four months to 61 years at the start of treatment.
Report Scope
|
Report Attribute |
Details |
|
Market Value in 2023 |
US$ 18 million |
|
Market Value in 2033 |
US$ 41.07 million |
|
Growth Rate |
CAGR of 8.6% from 2023 to 2033 |
|
Base Year for Estimation |
2022 |
|
Historical Data |
2018 to 2022 |
|
Forecast Period |
2023 to 2033 |
|
Quantitative Units |
Revenue in US$ Million and CAGR from 2023 to 2033 |
|
Report Coverage |
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
|
Segments Covered |
|
|
Regions Covered |
|
|
Key Countries Profiled |
|
|
Key Companies Profiled |
|
|
Customization |
Available Upon Request |
Key Segments Profiled in the Primary Hyperoxaluria Treatment Industry Survey
Type:
- Type 1
- Type 2
- Type 3
Drug Class:
- Pyridoxine
- Potassium Citrate
- Thiazides
- Orthophosphates
Route of Administration:
- Oral
- Intravenous
Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East & Africa
Frequently Asked Questions
At what rate did the primary hyperoxaluria treatment market flourish from 2018 to 2022?
From 2018 to 2022, the primary hyperoxaluria treatment market grew at a CAGR of 5.2%.
What will be the growth rate of the global primary hyperoxaluria treatment market during the forecast period?
The global primary hyperoxaluria treatment market is expected to grow with an 8.6% CAGR from 2023 to 2033.
What will be the projected market size of the primary hyperoxaluria treatment market by 2033?
As of 2033, the primary hyperoxaluria treatment market is expected to reach US$ 41.07 million
Which distribution channel is expected to dominate the global primary hyperoxaluria treatment market during 2033?
According to the FMI analysis, the hospital pharmacies segment accounts for the largest market share.
How is the North American primary hyperoxaluria treatment market projected to grow in 2023?
North America is expected to possess a 40% market share for the primary hyperoxaluria treatment market in 2023
Table of Content
1. Executive Summary | Primary Hyperoxaluria Treatment Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Type, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type, 2023 to 2033 5.3.1. Type 1 5.3.2. Type 2 5.3.3. Type 3 5.4. Y-o-Y Growth Trend Analysis By Type, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Type, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033 6.3.1. Pyridoxine 6.3.2. Potassium Citrate 6.3.3. Thiazides 6.3.4. Orthophosphates 6.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration , 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration , 2023 to 2033 7.3.1. Oral 7.3.2. Intravenous 7.4. Y-o-Y Growth Trend Analysis By Route of Administration , 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Route of Administration , 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 8.1. Introduction / Key Findings 8.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022 8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033 8.3.1. Hospital pharmacies 8.3.2. Retail pharmacies 8.3.3. Online pharmacies 8.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022 8.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 9.1. Introduction 9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 9.3.1. North America 9.3.2. Latin America 9.3.3. Europe 9.3.4. South Asia 9.3.5. East Asia 9.3.6. Oceania 9.3.7. Middle East & Africa 9.4. Market Attractiveness Analysis By Region 10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. United States 10.2.1.2. Canada 10.2.2. By Type 10.2.3. By Drug Class 10.2.4. By Route of Administration 10.2.5. By Distribution Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Type 10.3.3. By Drug Class 10.3.4. By Route of Administration 10.3.5. By Distribution Channel 10.4. Key Takeaways 11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Brazil 11.2.1.2. Mexico 11.2.1.3. Rest of Latin America 11.2.2. By Type 11.2.3. By Drug Class 11.2.4. By Route of Administration 11.2.5. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Type 11.3.3. By Drug Class 11.3.4. By Route of Administration 11.3.5. By Distribution Channel 11.4. Key Takeaways 12. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. Germany 12.2.1.2. United Kingdom 12.2.1.3. France 12.2.1.4. Spain 12.2.1.5. Italy 12.2.1.6. Rest of Europe 12.2.2. By Type 12.2.3. By Drug Class 12.2.4. By Route of Administration 12.2.5. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Type 12.3.3. By Drug Class 12.3.4. By Route of Administration 12.3.5. By Distribution Channel 12.4. Key Takeaways 13. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. India 13.2.1.2. Malaysia 13.2.1.3. Singapore 13.2.1.4. Thailand 13.2.1.5. Rest of South Asia 13.2.2. By Type 13.2.3. By Drug Class 13.2.4. By Route of Administration 13.2.5. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Type 13.3.3. By Drug Class 13.3.4. By Route of Administration 13.3.5. By Distribution Channel 13.4. Key Takeaways 14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. China 14.2.1.2. Japan 14.2.1.3. South Korea 14.2.2. By Type 14.2.3. By Drug Class 14.2.4. By Route of Administration 14.2.5. By Distribution Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Type 14.3.3. By Drug Class 14.3.4. By Route of Administration 14.3.5. By Distribution Channel 14.4. Key Takeaways 15. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. Australia 15.2.1.2. New Zealand 15.2.2. By Type 15.2.3. By Drug Class 15.2.4. By Route of Administration 15.2.5. By Distribution Channel 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Type 15.3.3. By Drug Class 15.3.4. By Route of Administration 15.3.5. By Distribution Channel 15.4. Key Takeaways 16. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 16.2.1. By Country 16.2.1.1. GCC Countries 16.2.1.2. South Africa 16.2.1.3. Israel 16.2.1.4. Rest of MEA 16.2.2. By Type 16.2.3. By Drug Class 16.2.4. By Route of Administration 16.2.5. By Distribution Channel 16.3. Market Attractiveness Analysis 16.3.1. By Country 16.3.2. By Type 16.3.3. By Drug Class 16.3.4. By Route of Administration 16.3.5. By Distribution Channel 16.4. Key Takeaways 17. Key Countries Market Analysis 17.1. USA 17.1.1. Pricing Analysis 17.1.2. Market Share Analysis, 2022 17.1.2.1. By Type 17.1.2.2. By Drug Class 17.1.2.3. By Route of Administration 17.1.2.4. By Distribution Channel 17.2. Canada 17.2.1. Pricing Analysis 17.2.2. Market Share Analysis, 2022 17.2.2.1. By Type 17.2.2.2. By Drug Class 17.2.2.3. By Route of Administration 17.2.2.4. By Distribution Channel 17.3. Brazil 17.3.1. Pricing Analysis 17.3.2. Market Share Analysis, 2022 17.3.2.1. By Type 17.3.2.2. By Drug Class 17.3.2.3. By Route of Administration 17.3.2.4. By Distribution Channel 17.4. Mexico 17.4.1. Pricing Analysis 17.4.2. Market Share Analysis, 2022 17.4.2.1. By Type 17.4.2.2. By Drug Class 17.4.2.3. By Route of Administration 17.4.2.4. By Distribution Channel 17.5. Germany 17.5.1. Pricing Analysis 17.5.2. Market Share Analysis, 2022 17.5.2.1. By Type 17.5.2.2. By Drug Class 17.5.2.3. By Route of Administration 17.5.2.4. By Distribution Channel 17.6. United kingdom 17.6.1. Pricing Analysis 17.6.2. Market Share Analysis, 2022 17.6.2.1. By Type 17.6.2.2. By Drug Class 17.6.2.3. By Route of Administration 17.6.2.4. By Distribution Channel 17.7. France 17.7.1. Pricing Analysis 17.7.2. Market Share Analysis, 2022 17.7.2.1. By Type 17.7.2.2. By Drug Class 17.7.2.3. By Route of Administration 17.7.2.4. By Distribution Channel 17.8. Spain 17.8.1. Pricing Analysis 17.8.2. Market Share Analysis, 2022 17.8.2.1. By Type 17.8.2.2. By Drug Class 17.8.2.3. By Route of Administration 17.8.2.4. By Distribution Channel 17.9. Italy 17.9.1. Pricing Analysis 17.9.2. Market Share Analysis, 2022 17.9.2.1. By Type 17.9.2.2. By Drug Class 17.9.2.3. By Route of Administration 17.9.2.4. By Distribution Channel 17.10. India 17.10.1. Pricing Analysis 17.10.2. Market Share Analysis, 2022 17.10.2.1. By Type 17.10.2.2. By Drug Class 17.10.2.3. By Route of Administration 17.10.2.4. By Distribution Channel 17.11. Malaysia 17.11.1. Pricing Analysis 17.11.2. Market Share Analysis, 2022 17.11.2.1. By Type 17.11.2.2. By Drug Class 17.11.2.3. By Route of Administration 17.11.2.4. By Distribution Channel 17.12. Singapore 17.12.1. Pricing Analysis 17.12.2. Market Share Analysis, 2022 17.12.2.1. By Type 17.12.2.2. By Drug Class 17.12.2.3. By Route of Administration 17.12.2.4. By Distribution Channel 17.13. Thailand 17.13.1. Pricing Analysis 17.13.2. Market Share Analysis, 2022 17.13.2.1. By Type 17.13.2.2. By Drug Class 17.13.2.3. By Route of Administration 17.13.2.4. By Distribution Channel 17.14. China 17.14.1. Pricing Analysis 17.14.2. Market Share Analysis, 2022 17.14.2.1. By Type 17.14.2.2. By Drug Class 17.14.2.3. By Route of Administration 17.14.2.4. By Distribution Channel 17.15. Japan 17.15.1. Pricing Analysis 17.15.2. Market Share Analysis, 2022 17.15.2.1. By Type 17.15.2.2. By Drug Class 17.15.2.3. By Route of Administration 17.15.2.4. By Distribution Channel 17.16. South Korea 17.16.1. Pricing Analysis 17.16.2. Market Share Analysis, 2022 17.16.2.1. By Type 17.16.2.2. By Drug Class 17.16.2.3. By Route of Administration 17.16.2.4. By Distribution Channel 17.17. Australia 17.17.1. Pricing Analysis 17.17.2. Market Share Analysis, 2022 17.17.2.1. By Type 17.17.2.2. By Drug Class 17.17.2.3. By Route of Administration 17.17.2.4. By Distribution Channel 17.18. New Zealand 17.18.1. Pricing Analysis 17.18.2. Market Share Analysis, 2022 17.18.2.1. By Type 17.18.2.2. By Drug Class 17.18.2.3. By Route of Administration 17.18.2.4. By Distribution Channel 17.19. GCC Countries 17.19.1. Pricing Analysis 17.19.2. Market Share Analysis, 2022 17.19.2.1. By Type 17.19.2.2. By Drug Class 17.19.2.3. By Route of Administration 17.19.2.4. By Distribution Channel 17.20. South Africa 17.20.1. Pricing Analysis 17.20.2. Market Share Analysis, 2022 17.20.2.1. By Type 17.20.2.2. By Drug Class 17.20.2.3. By Route of Administration 17.20.2.4. By Distribution Channel 17.21. Israel 17.21.1. Pricing Analysis 17.21.2. Market Share Analysis, 2022 17.21.2.1. By Type 17.21.2.2. By Drug Class 17.21.2.3. By Route of Administration 17.21.2.4. By Distribution Channel 18. Market Structure Analysis 18.1. Competition Dashboard 18.2. Competition Benchmarking 18.3. Market Share Analysis of Top Players 18.3.1. By Regional 18.3.2. By Type 18.3.3. By Drug Class 18.3.4. By Route of Administration 18.3.5. By Distribution Channel 19. Competition Analysis 19.1. Competition Deep Dive 19.1.1. Alnylum Pharma 19.1.1.1. Overview 19.1.1.2. Product Portfolio 19.1.1.3. Profitability by Market Segments 19.1.1.4. Sales Footprint 19.1.1.5. Strategy Overview 19.1.1.5.1. Marketing Strategy 19.1.2. OxThera 19.1.2.1. Overview 19.1.2.2. Product Portfolio 19.1.2.3. Profitability by Market Segments 19.1.2.4. Sales Footprint 19.1.2.5. Strategy Overview 19.1.2.5.1. Marketing Strategy 19.1.3. Dicerna Pharmaceuticals, Inc. 19.1.3.1. Overview 19.1.3.2. Product Portfolio 19.1.3.3. Profitability by Market Segments 19.1.3.4. Sales Footprint 19.1.3.5. Strategy Overview 19.1.3.5.1. Marketing Strategy 19.1.4. Allena Pharmaceuticals 19.1.4.1. Overview 19.1.4.2. Product Portfolio 19.1.4.3. Profitability by Market Segments 19.1.4.4. Sales Footprint 19.1.4.5. Strategy Overview 19.1.4.5.1. Marketing Strategy 19.1.5. Biocodex 19.1.5.1. Overview 19.1.5.2. Product Portfolio 19.1.5.3. Profitability by Market Segments 19.1.5.4. Sales Footprint 19.1.5.5. Strategy Overview 19.1.5.5.1. Marketing Strategy 19.1.6. Tecoland Corporation 19.1.6.1. Overview 19.1.6.2. Product Portfolio 19.1.6.3. Profitability by Market Segments 19.1.6.4. Sales Footprint 19.1.6.5. Strategy Overview 19.1.6.5.1. Marketing Strategy 19.1.7. Zhejiang Tianxin Pharmaceutical Co. 19.1.7.1. Overview 19.1.7.2. Product Portfolio 19.1.7.3. Profitability by Market Segments 19.1.7.4. Sales Footprint 19.1.7.5. Strategy Overview 19.1.7.5.1. Marketing Strategy 19.1.8. Takeda Pharmaceuticals 19.1.8.1. Overview 19.1.8.2. Product Portfolio 19.1.8.3. Profitability by Market Segments 19.1.8.4. Sales Footprint 19.1.8.5. Strategy Overview 19.1.8.5.1. Marketing Strategy 19.1.9. Wuxi Further Pharmaceutical Co Ltd 19.1.9.1. Overview 19.1.9.2. Product Portfolio 19.1.9.3. Profitability by Market Segments 19.1.9.4. Sales Footprint 19.1.9.5. Strategy Overview 19.1.9.5.1. Marketing Strategy 19.1.10. Genentech 19.1.10.1. Overview 19.1.10.2. Product Portfolio 19.1.10.3. Profitability by Market Segments 19.1.10.4. Sales Footprint 19.1.10.5. Strategy Overview 19.1.10.5.1. Marketing Strategy 20. Assumptions & Acronyms Used 21. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033 Table 2: Global Market Value (US$ Million) Forecast by Type, 2018 to 2033 Table 3: Global Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 4: Global Market Value (US$ Million) Forecast by Route of Administration , 2018 to 2033 Table 5: Global Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 6: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 7: North America Market Value (US$ Million) Forecast by Type, 2018 to 2033 Table 8: North America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 9: North America Market Value (US$ Million) Forecast by Route of Administration , 2018 to 2033 Table 10: North America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 11: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 12: Latin America Market Value (US$ Million) Forecast by Type, 2018 to 2033 Table 13: Latin America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 14: Latin America Market Value (US$ Million) Forecast by Route of Administration , 2018 to 2033 Table 15: Latin America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 16: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 17: Europe Market Value (US$ Million) Forecast by Type, 2018 to 2033 Table 18: Europe Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 19: Europe Market Value (US$ Million) Forecast by Route of Administration , 2018 to 2033 Table 20: Europe Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 21: South Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 22: South Asia Market Value (US$ Million) Forecast by Type, 2018 to 2033 Table 23: South Asia Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 24: South Asia Market Value (US$ Million) Forecast by Route of Administration , 2018 to 2033 Table 25: South Asia Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 26: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 27: East Asia Market Value (US$ Million) Forecast by Type, 2018 to 2033 Table 28: East Asia Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 29: East Asia Market Value (US$ Million) Forecast by Route of Administration , 2018 to 2033 Table 30: East Asia Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 31: Oceania Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 32: Oceania Market Value (US$ Million) Forecast by Type, 2018 to 2033 Table 33: Oceania Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 34: Oceania Market Value (US$ Million) Forecast by Route of Administration , 2018 to 2033 Table 35: Oceania Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 36: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 37: MEA Market Value (US$ Million) Forecast by Type, 2018 to 2033 Table 38: MEA Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 39: MEA Market Value (US$ Million) Forecast by Route of Administration , 2018 to 2033 Table 40: MEA Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Market Value (US$ Million) by Type, 2023 to 2033 Figure 2: Global Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 3: Global Market Value (US$ Million) by Route of Administration, 2023 to 2033 Figure 4: Global Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 5: Global Market Value (US$ Million) by Region, 2023 to 2033 Figure 6: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033 Figure 7: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033 Figure 8: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033 Figure 9: Global Market Value (US$ Million) Analysis by Type, 2018 to 2033 Figure 10: Global Market Value Share (%) and BPS Analysis by Type, 2023 to 2033 Figure 11: Global Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033 Figure 12: Global Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 13: Global Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 14: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 15: Global Market Value (US$ Million) Analysis by Route of Administration , 2018 to 2033 Figure 16: Global Market Value Share (%) and BPS Analysis by Route of Administration , 2023 to 2033 Figure 17: Global Market Y-o-Y Growth (%) Projections by Route of Administration , 2023 to 2033 Figure 18: Global Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 19: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 20: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 21: Global Market Attractiveness by Type, 2023 to 2033 Figure 22: Global Market Attractiveness by Drug Class, 2023 to 2033 Figure 23: Global Market Attractiveness by Route of Administration , 2023 to 2033 Figure 24: Global Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 25: Global Market Attractiveness by Region, 2023 to 2033 Figure 26: North America Market Value (US$ Million) by Type, 2023 to 2033 Figure 27: North America Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 28: North America Market Value (US$ Million) by Route of Administration , 2023 to 2033 Figure 29: North America Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 30: North America Market Value (US$ Million) by Country, 2023 to 2033 Figure 31: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 32: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 33: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 34: North America Market Value (US$ Million) Analysis by Type, 2018 to 2033 Figure 35: North America Market Value Share (%) and BPS Analysis by Type, 2023 to 2033 Figure 36: North America Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033 Figure 37: North America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 38: North America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 39: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 40: North America Market Value (US$ Million) Analysis by Route of Administration , 2018 to 2033 Figure 41: North America Market Value Share (%) and BPS Analysis by Route of Administration , 2023 to 2033 Figure 42: North America Market Y-o-Y Growth (%) Projections by Route of Administration , 2023 to 2033 Figure 43: North America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 44: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 45: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 46: North America Market Attractiveness by Type, 2023 to 2033 Figure 47: North America Market Attractiveness by Drug Class, 2023 to 2033 Figure 48: North America Market Attractiveness by Route of Administration , 2023 to 2033 Figure 49: North America Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 50: North America Market Attractiveness by Country, 2023 to 2033 Figure 51: Latin America Market Value (US$ Million) by Type, 2023 to 2033 Figure 52: Latin America Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 53: Latin America Market Value (US$ Million) by Route of Administration , 2023 to 2033 Figure 54: Latin America Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 55: Latin America Market Value (US$ Million) by Country, 2023 to 2033 Figure 56: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 57: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 58: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 59: Latin America Market Value (US$ Million) Analysis by Type, 2018 to 2033 Figure 60: Latin America Market Value Share (%) and BPS Analysis by Type, 2023 to 2033 Figure 61: Latin America Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033 Figure 62: Latin America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 63: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 64: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 65: Latin America Market Value (US$ Million) Analysis by Route of Administration , 2018 to 2033 Figure 66: Latin America Market Value Share (%) and BPS Analysis by Route of Administration , 2023 to 2033 Figure 67: Latin America Market Y-o-Y Growth (%) Projections by Route of Administration , 2023 to 2033 Figure 68: Latin America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 69: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 70: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 71: Latin America Market Attractiveness by Type, 2023 to 2033 Figure 72: Latin America Market Attractiveness by Drug Class, 2023 to 2033 Figure 73: Latin America Market Attractiveness by Route of Administration , 2023 to 2033 Figure 74: Latin America Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 75: Latin America Market Attractiveness by Country, 2023 to 2033 Figure 76: Europe Market Value (US$ Million) by Type, 2023 to 2033 Figure 77: Europe Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 78: Europe Market Value (US$ Million) by Route of Administration , 2023 to 2033 Figure 79: Europe Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 80: Europe Market Value (US$ Million) by Country, 2023 to 2033 Figure 81: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 82: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 83: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 84: Europe Market Value (US$ Million) Analysis by Type, 2018 to 2033 Figure 85: Europe Market Value Share (%) and BPS Analysis by Type, 2023 to 2033 Figure 86: Europe Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033 Figure 87: Europe Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 88: Europe Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 89: Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 90: Europe Market Value (US$ Million) Analysis by Route of Administration , 2018 to 2033 Figure 91: Europe Market Value Share (%) and BPS Analysis by Route of Administration , 2023 to 2033 Figure 92: Europe Market Y-o-Y Growth (%) Projections by Route of Administration , 2023 to 2033 Figure 93: Europe Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 94: Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 95: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 96: Europe Market Attractiveness by Type, 2023 to 2033 Figure 97: Europe Market Attractiveness by Drug Class, 2023 to 2033 Figure 98: Europe Market Attractiveness by Route of Administration , 2023 to 2033 Figure 99: Europe Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 100: Europe Market Attractiveness by Country, 2023 to 2033 Figure 101: South Asia Market Value (US$ Million) by Type, 2023 to 2033 Figure 102: South Asia Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 103: South Asia Market Value (US$ Million) by Route of Administration , 2023 to 2033 Figure 104: South Asia Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 105: South Asia Market Value (US$ Million) by Country, 2023 to 2033 Figure 106: South Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 107: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 108: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 109: South Asia Market Value (US$ Million) Analysis by Type, 2018 to 2033 Figure 110: South Asia Market Value Share (%) and BPS Analysis by Type, 2023 to 2033 Figure 111: South Asia Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033 Figure 112: South Asia Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 113: South Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 114: South Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 115: South Asia Market Value (US$ Million) Analysis by Route of Administration , 2018 to 2033 Figure 116: South Asia Market Value Share (%) and BPS Analysis by Route of Administration , 2023 to 2033 Figure 117: South Asia Market Y-o-Y Growth (%) Projections by Route of Administration , 2023 to 2033 Figure 118: South Asia Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 119: South Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 120: South Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 121: South Asia Market Attractiveness by Type, 2023 to 2033 Figure 122: South Asia Market Attractiveness by Drug Class, 2023 to 2033 Figure 123: South Asia Market Attractiveness by Route of Administration , 2023 to 2033 Figure 124: South Asia Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 125: South Asia Market Attractiveness by Country, 2023 to 2033 Figure 126: East Asia Market Value (US$ Million) by Type, 2023 to 2033 Figure 127: East Asia Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 128: East Asia Market Value (US$ Million) by Route of Administration , 2023 to 2033 Figure 129: East Asia Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 130: East Asia Market Value (US$ Million) by Country, 2023 to 2033 Figure 131: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 132: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 133: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 134: East Asia Market Value (US$ Million) Analysis by Type, 2018 to 2033 Figure 135: East Asia Market Value Share (%) and BPS Analysis by Type, 2023 to 2033 Figure 136: East Asia Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033 Figure 137: East Asia Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 138: East Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 139: East Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 140: East Asia Market Value (US$ Million) Analysis by Route of Administration , 2018 to 2033 Figure 141: East Asia Market Value Share (%) and BPS Analysis by Route of Administration , 2023 to 2033 Figure 142: East Asia Market Y-o-Y Growth (%) Projections by Route of Administration , 2023 to 2033 Figure 143: East Asia Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 144: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 145: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 146: East Asia Market Attractiveness by Type, 2023 to 2033 Figure 147: East Asia Market Attractiveness by Drug Class, 2023 to 2033 Figure 148: East Asia Market Attractiveness by Route of Administration , 2023 to 2033 Figure 149: East Asia Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 150: East Asia Market Attractiveness by Country, 2023 to 2033 Figure 151: Oceania Market Value (US$ Million) by Type, 2023 to 2033 Figure 152: Oceania Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 153: Oceania Market Value (US$ Million) by Route of Administration , 2023 to 2033 Figure 154: Oceania Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 155: Oceania Market Value (US$ Million) by Country, 2023 to 2033 Figure 156: Oceania Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 157: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 158: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 159: Oceania Market Value (US$ Million) Analysis by Type, 2018 to 2033 Figure 160: Oceania Market Value Share (%) and BPS Analysis by Type, 2023 to 2033 Figure 161: Oceania Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033 Figure 162: Oceania Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 163: Oceania Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 164: Oceania Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 165: Oceania Market Value (US$ Million) Analysis by Route of Administration , 2018 to 2033 Figure 166: Oceania Market Value Share (%) and BPS Analysis by Route of Administration , 2023 to 2033 Figure 167: Oceania Market Y-o-Y Growth (%) Projections by Route of Administration , 2023 to 2033 Figure 168: Oceania Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 169: Oceania Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 170: Oceania Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 171: Oceania Market Attractiveness by Type, 2023 to 2033 Figure 172: Oceania Market Attractiveness by Drug Class, 2023 to 2033 Figure 173: Oceania Market Attractiveness by Route of Administration , 2023 to 2033 Figure 174: Oceania Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 175: Oceania Market Attractiveness by Country, 2023 to 2033 Figure 176: MEA Market Value (US$ Million) by Type, 2023 to 2033 Figure 177: MEA Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 178: MEA Market Value (US$ Million) by Route of Administration , 2023 to 2033 Figure 179: MEA Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 180: MEA Market Value (US$ Million) by Country, 2023 to 2033 Figure 181: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 182: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 183: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 184: MEA Market Value (US$ Million) Analysis by Type, 2018 to 2033 Figure 185: MEA Market Value Share (%) and BPS Analysis by Type, 2023 to 2033 Figure 186: MEA Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033 Figure 187: MEA Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 188: MEA Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 189: MEA Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 190: MEA Market Value (US$ Million) Analysis by Route of Administration , 2018 to 2033 Figure 191: MEA Market Value Share (%) and BPS Analysis by Route of Administration , 2023 to 2033 Figure 192: MEA Market Y-o-Y Growth (%) Projections by Route of Administration , 2023 to 2033 Figure 193: MEA Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 194: MEA Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 195: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 196: MEA Market Attractiveness by Type, 2023 to 2033 Figure 197: MEA Market Attractiveness by Drug Class, 2023 to 2033 Figure 198: MEA Market Attractiveness by Route of Administration , 2023 to 2033 Figure 199: MEA Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 200: MEA Market Attractiveness by Country, 2023 to 2033
Recommendations
Explore Healthcare Insights
View Reports
